<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medical Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1752-1947</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26951070</article-id>
      <article-id pub-id-type="pmc">4782328</article-id>
      <article-id pub-id-type="publisher-id">806</article-id>
      <article-id pub-id-type="doi">10.1186/s13256-016-0806-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ohtaka</surname>
            <given-names>Mari</given-names>
          </name>
          <address>
            <email>marimo633@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7049-3379</contrib-id>
          <name>
            <surname>Kawahara</surname>
            <given-names>Takashi</given-names>
          </name>
          <address>
            <phone>+81-45-786-5775</phone>
            <email>takashi_tk2001@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kumano</surname>
            <given-names>Yohei</given-names>
          </name>
          <address>
            <email>y.kumano.2925@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maeda</surname>
            <given-names>Yoko</given-names>
          </name>
          <address>
            <email>yocomn_comn@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kondo</surname>
            <given-names>Takuya</given-names>
          </name>
          <address>
            <email>T.Kondo0807@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mochizuki</surname>
            <given-names>Taku</given-names>
          </name>
          <address>
            <email>apotaku24@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishida</surname>
            <given-names>Hiroaki</given-names>
          </name>
          <address>
            <email>temp4@kamakura-medical.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hattori</surname>
            <given-names>Yusuke</given-names>
          </name>
          <address>
            <email>hatu98@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teranishi</surname>
            <given-names>Jun-ichi</given-names>
          </name>
          <address>
            <email>jteran@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miyoshi</surname>
            <given-names>Yasuhide</given-names>
          </name>
          <address>
            <email>miyoyasu@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yumura</surname>
            <given-names>Yasushi</given-names>
          </name>
          <address>
            <email>yumura@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yao</surname>
            <given-names>Masahiro</given-names>
          </name>
          <address>
            <email>masayao@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Inayama</surname>
            <given-names>Yoshiaki</given-names>
          </name>
          <address>
            <email>inayama@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uemura</surname>
            <given-names>Hiroji</given-names>
          </name>
          <address>
            <email>hu0428@yokohama-cu.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57 Urafune-cho Minami-ku, Yokohama, 232-0024 Japan </aff>
        <aff id="Aff2"><label/>Department of Urology, Yokohama City University Graduate School of Medicine, 4-57 Urafune-cho Minami-ku, Yokohama, 232-0024 Japan </aff>
        <aff id="Aff3"><label/>Department of Diagnostic Pathology, Yokohama City University Medical Center, 4-57 Urafune-cho Minami-ku, Yokohama, 232-0024 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>8</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>48</elocation-id>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>1</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Ohtaka et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, is a rare histological type of bladder cancer similar to plasma cells and is an aggressive variant of urothelial carcinoma associated with a poor prognosis.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 41-year-old Asian man was referred to our hospital due to macroscopic hematuria. Cystoscopy detected a non-papillary tumor, and a transurethral resection of the bladder tumor revealed pT1N0M0 bladder cancer. A pathological examination showed high-grade invasive urothelial carcinoma and a component of signet ring cell carcinoma. A follow-up of the transurethral resection with radical cystectomy was carried out, and a pathological examination showed infiltrating urothelial carcinoma, with partial features of the plasmacytoid variant. We added chemotherapy treatment with gemcitabine and cisplatin for two cycles. Our patient has been free from recurrence for 2&#xA0;years.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>We herein report the case of a patient with a plasmacytoid variant of urothelial carcinoma controlled with radial cystectomy and subsequent chemotherapy.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Urothelial carcinoma</kwd>
        <kwd>Plasmacytoid variant</kwd>
        <kwd>Gemcitabine</kwd>
        <kwd>Cisplatin</kwd>
        <kwd>Radical cystectomy</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant (PUC), is a rare histological type of bladder cancer similar to plasma cells and is an aggressive variant of urothelial carcinoma (UC) associated with a poor prognosis. The first report for PUC was provided by Sahin <italic>et al.</italic>; to date, only approximately 100 cases of PUC have been reported in the English literature [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>]. We herein report a case of a patient with plasmacytoid urothelial carcinoma that was successfully controlled with chemotherapy following radical cystectomy.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 41-year-old Asian man was referred to our hospital due to macroscopic hematuria. His past history included middle ear cholesteatoma and he had no smoking history. Cystoscopy detected a non-papillary tumor, and a transurethral resection of the bladder tumor (TUR-Bt) and a magnetic resonance imaging (MRI) scan revealed cT3N0M0 bladder cancer.</p>
      <sec id="Sec3">
        <title>Laboratory data at the time of admission</title>
        <p>The hematological and biochemical data showed no abnormal findings. A urinary analysis resulted in the following: pH&#xA0;6.5, red blood cell count 10&#x2013;19/high-power field (HPF), white blood cell count 1&#x2013;4/HPF, protein negative, and glucose negative. The urinary cytology was class III.</p>
      </sec>
      <sec id="Sec4">
        <title>Imaging findings</title>
        <p>An MRI scan showed that the tumor extended over the bladder, as seen in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. No obvious distal and local lymphadenopathy was observed on a non-contrast computed tomography (CT) scan.<fig id="Fig1"><label>Fig. 1</label><caption><p>Magnetic resonance imaging findings in (<bold>a</bold>) T2-weighted and (<bold>b</bold>) diffusion-weighted images. The mass was believed to be invasive outside of the bladder wall (<italic>arrow</italic>)</p></caption><graphic xlink:href="13256_2016_806_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec5">
        <title>Operative procedure</title>
        <p>Our patient underwent a TUR-Bt, and a pathological examination revealed urothelial carcinoma (high-grade, pT1, G2) and signet ring cell carcinoma was found in a portion of the bladder tumor. Two months after the TUR-Bt, a radical cystectomy was performed according to the tumor grade of malignancy and the imaging findings (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>A surgical specimen from the radical cystectomy. The tumor was located in the bladder trigone (<italic>arrow</italic>)</p></caption><graphic xlink:href="13256_2016_806_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Pathological findings</title>
        <p>Grossly, the infiltrating neoplasm, measuring 25 &#xD7; 20&#xA0;mm in size, was located in the bladder trigone. The pathological stage was pT2bN0M0. Histologically, the neoplasm was composed of isolated atypical cells that had relatively abundant eosinophilic cytoplasm with eccentric nuclei, showing moderate pleomorphism. Perinuclear pale regions were occasionally seen. These features partly resembled plasma cells (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). The immunohistochemical profile of the tumor cells was positive for keratin CAM5.2 and CK20, but negative for CK7, CD56, chromogranin A, synaptophysin, CD20, CD79a, kappa and lambda. Thus, the diagnosis of infiltrating high-grade urothelial carcinoma, plasmacytoid variant, was made. Plasma cells have a similar form to signet ring cells, thus it is difficult to distinguish these cells. However, plasma cells frequently show CD138 positivity, which may be useful for discriminating between the two types of cells.<fig id="Fig3"><label>Fig. 3</label><caption><p>Hematoxylin and eosin stain. Plasmacytoid urothelial carcinoma was characterized by isolated cells with uneven nuclear distribution. Invasive plasma cell was founded sparsely (<italic>enlarged part of image</italic>)</p></caption><graphic xlink:href="13256_2016_806_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec7">
        <title>Immunohistochemistry for PD-1 and PD-L1</title>
        <p>An immunohistochemical analysis was performed on 5-&#x3BC;m-thick sections. The slides were dewaxed with xylene and hydrated with gradient ethanol, and microwaved at the high level for 2&#xA0;minutes and then at the medium-low level for 30&#xA0;minutes for heat antigen retrieval (Target Retrieval Solution pH&#xA0;9, Dako, Carpinteria, CA, USA). After 3&#xA0;% hydrogen peroxidase blocking, the samples were incubated overnight at 4&#xA0;&#xB0;C with a primary antibody to PD-1 (dilution 1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or PD-L1 (dilution 1:50, Santa Cruz Biotechnology). The slides were then treated with a broad-spectrum secondary antibody (Invitrogen, Grand Island, NY, USA) and washed (Envision FLEX Wash Buffer, Dako). After diaminobenzidine staining, the slides were counterstained with hematoxylin, dehydrated with gradient ethanol and xylene, and then sealed. There were no positive finding (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Immunohistochemistry for PD-1 (<bold>a</bold>) and PD-L1 (<bold>b</bold>) expression. There was no positive expression in both PD-1 and PD-L1</p></caption><graphic xlink:href="13256_2016_806_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
      <sec id="Sec8">
        <title>Postoperative course</title>
        <p>Two months after the total cystectomy, adjuvant chemotherapy with gemcitabine and cisplatin was administered (G: 2,000&#xA0;mg/m<sup>2</sup>, C: 63&#xA0;mg/m<sup>2</sup>). We used the following dosing schedule: day 1&#xA0;G: 1,000&#xA0;mg/m<sup>2</sup>, day 2 C: 63&#xA0;mg/m<sup>2</sup>, and day 8&#xA0;G: 1,000&#xA0;mg/m<sup>2</sup> that was administered in two cycles. No adverse event was observed. We followed up our patient with cytology and a CT scan every 3&#xA0;months. Our patient has not experienced any recurrence of bladder cancer for 2&#xA0;years following the radical cystectomy.</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Discussion</title>
      <p>PUC is a rare histological type of bladder cancer similar to plasma cells and is an aggressive variant of UC associated with a poor prognosis [<xref ref-type="bibr" rid="CR6">6</xref>]. The first case of PUC was reported by Sahin <italic>et al</italic>.; to date, only approximately100 cases of PUC have been reported in the English literature [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Most patients were in their 60s; the male-to-female ratio was 9:1. This variant is typically diagnosed at an advanced pathological stage (64&#xA0;% pT3, 23&#xA0;% pT4), showing metastases in 60&#xA0;% of the patients [<xref ref-type="bibr" rid="CR3">3</xref>]. This tumor initially presents as a high-grade, high-stage lesion, and diffusely invades the bladder wall; however, patients have no specific symptoms, which can lead to a delayed diagnosis and poor prognosis. Furthermore, PUC is difficult to differentiate from signet ring cell carcinoma of the urinary bladder due to overlap in the clinical and morphological presentation [<xref ref-type="bibr" rid="CR4">4</xref>]. In the present case, the initial diagnosis was signet ring cell carcinoma, thus we performed a radical cystectomy because of the poor prognosis. However, the subsequent pathological examination revealed infiltrating high-grade urothelial carcinoma with partial features of the plasmacytoid variant, thus we administered chemotherapy.</p>
      <p>Most urological guidelines recommend adjuvant cisplatin-based chemotherapy as the therapy of choice in locally advanced bladder cancer. However, it has been reported that tumors with variant histology are associated with a higher risk of progression than conventional high-grade UC. Keck <italic>et al.</italic> reported that patients suffering from PUC have the worst clinical outcome regarding overall survival compared to conventional UC [<xref ref-type="bibr" rid="CR7">7</xref>]. We searched for other cases of PUC that were treated with cystectomy and chemotherapy. Almost all cases were treated with cystectomy and adjuvant chemotherapy. All cases were at an advanced stage, and the chemotherapy consisted of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) or GC. Cystectomy and adjuvant chemotherapy with GC was relatively effective for the management of PUC in terms of overall survival (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Furthermore, Kaimakliotis <italic>et al.</italic> reported that the management of PUC should be aggressive and that cystectomy should be performed at all stages [<xref ref-type="bibr" rid="CR8">8</xref>]. They also reported that although it is unclear whether PUC is independently associated with a poor prognosis, the prognosis in PUC is poor due to the higher stage at the time of diagnosis [<xref ref-type="bibr" rid="CR9">9</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>The cases of PUC that were treated with cystectomy and adjuvant chemotherapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>First author</th><th>TNM stage</th><th>Chemotherapy</th><th>Outcome</th><th>OS</th></tr></thead><tbody><tr><td>Kohno [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td>T4N0M0</td><td>M-VAC&#xD7;2</td><td>Survival</td><td>18&#xA0;m</td></tr><tr><td>Kawashima [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td>T3aN0M0</td><td>M-VAC&#xD7;2</td><td>Survival</td><td>11&#xA0;m</td></tr><tr><td>Fritsche [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td>T4bN2M0</td><td>GC&#xD7;4</td><td>Survival</td><td>16&#xA0;m</td></tr><tr><td/><td>T4aN0M0</td><td>GC&#xD7;5</td><td>Death</td><td>29&#xA0;m</td></tr><tr><td>Soylu [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td>T2bNxM0</td><td>5FU+leucovorin</td><td>Death</td><td>18&#xA0;m</td></tr><tr><td>Aldousari [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td>T3bN0M0</td><td>GC</td><td>Death</td><td>6&#xA0;m</td></tr><tr><td>Hayashi [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td>T4bN0M0</td><td>GC&#xD7;2</td><td>Death</td><td>9&#xA0;m</td></tr><tr><td>Present case</td><td>T2bN0M0</td><td>GC&#xD7;2</td><td>Survival</td><td>26&#xA0;m</td></tr></tbody></table><table-wrap-foot><p>
<italic>PUC</italic> invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, <italic>TNM</italic> tumor-node-metastasis, <italic>OS</italic> overall survival, <italic>M-VAC</italic> methotrexate, vinblastine, doxorubicin and cisplatin, <italic>GC</italic> gemcitabine and cisplatin, <italic>5FU</italic> 5-fluorouracil, <italic>m</italic> months</p></table-wrap-foot></table-wrap></p>
      <p>Recently, an anti-PD-L1 drug was found to have a rapid and ongoing response in patients with urothelial carcinoma in a phase 1 study. Interestingly, this drug showed higher efficacy in patients whose tumor-infiltrating cells showed high levels of <italic>PD-L1</italic> expression [<xref ref-type="bibr" rid="CR10">10</xref>]. Boorjian <italic>et al</italic>. reported that higher PD-L1 expression in tumor cells was associated with the presence of advanced disease in patients with urothelial carcinoma and that it was correlated with a poor prognosis after radical cystectomy [<xref ref-type="bibr" rid="CR11">11</xref>]. In our case, the tumor did not express PD-1 or PD-L1.</p>
      <p>Although we predicted a poor prognosis for this variant, the tumor was successfully treated with a combination of radical cystectomy and adjuvant chemotherapy, and our patient has remained free of any sign of recurrence of bladder cancer for 2&#xA0;years after the operation.</p>
    </sec>
    <sec id="Sec10">
      <title>Conclusions</title>
      <p>We herein described the case of a patient with PUC controlled with chemotherapy following radical cystectomy.</p>
    </sec>
    <sec id="Sec11">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CT</term>
          <def>
            <p>Computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>GC</term>
          <def>
            <p>Gemcitabine and cisplatin</p>
          </def>
        </def-item>
        <def-item>
          <term>HPF</term>
          <def>
            <p>high-power field</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>Magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>M-VAC</term>
          <def>
            <p>Methotrexate, vinblastine, doxorubicin and cisplatin</p>
          </def>
        </def-item>
        <def-item>
          <term>PUC</term>
          <def>
            <p>Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant</p>
          </def>
        </def-item>
        <def-item>
          <term>TUR-Bt</term>
          <def>
            <p>Transurethral resection of a bladder tumor</p>
          </def>
        </def-item>
        <def-item>
          <term>UC</term>
          <def>
            <p>Urothelial carcinoma</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>MO, TM, HI, YH, JT, and YMa performed the operation and YK, YM, TKo, YH, and YY conducted the patient follow-up. YI performed the pathological diagnosis. MO and TKa conceived of the study, participated in its design and wrote the manuscript. YMi and HU helped to check the draft. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>Rie Shimizu supported the immunohistochemical study. Grants from the Uehara Memorial Foundation, the Tokyo Biochemical Research Foundation, the Japanese Foundation for Research and Promotion of Endoscopy, and an International Exchange Grant from Kato Memorial Bioscience Foundation were provided to TK. There are no applicable grant numbers.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhuang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review</article-title>
          <source>Int J Clin Exp Pathol.</source>
          <year>2012</year>
          <volume>5</volume>
          <fpage>601</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">22949945</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keck</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stoehr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wach</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rogler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hofstaedter</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma</article-title>
          <source>Int J Cancer.</source>
          <year>2011</year>
          <volume>129</volume>
          <fpage>346</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.25700</pub-id>
          <pub-id pub-id-type="pmid">20878954</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonzalez-Roibon</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Chaux</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Al-Hussain</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Osunkoya</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Bezerra</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Hicks</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder</article-title>
          <source>Hum Pathol.</source>
          <year>2013</year>
          <volume>44</volume>
          <fpage>612</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2012.07.009</pub-id>
          <pub-id pub-id-type="pmid">23084634</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Plasmacytoid urothelial carcinoma of the bladder</article-title>
          <source>Indian J Pathol Microbiol.</source>
          <year>2014</year>
          <volume>57</volume>
          <fpage>320</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="doi">10.4103/0377-4929.134730</pub-id>
          <pub-id pub-id-type="pmid">24943778</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sahin</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Myhre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ro</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Sneige</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dekmezian</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Ayala</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma</article-title>
          <source>Acta Cytol</source>
          <year>1991</year>
          <volume>35</volume>
          <fpage>277</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">1710402</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawahara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Oshiro</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sekiguchi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Makiyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Uemura</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy</article-title>
          <source>Int J Urol.</source>
          <year>2011</year>
          <volume>18</volume>
          <fpage>851</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2042.2011.02880.x</pub-id>
          <pub-id pub-id-type="pmid">22004222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keck</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wach</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stoehr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kunath</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bertz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy</article-title>
          <source>BMC Cancer.</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>71</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2407-13-71</pub-id>
          <pub-id pub-id-type="pmid">23394492</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaimakliotis</surname>
              <given-names>HZ</given-names>
            </name>
            <name>
              <surname>Monn</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Cary</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Pedrosa</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Rice</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Masterson</surname>
              <given-names>TA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?</article-title>
          <source>Urol Oncol.</source>
          <year>2014</year>
          <volume>32</volume>
          <fpage>833</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.urolonc.2014.03.008</pub-id>
          <pub-id pub-id-type="pmid">24954925</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaimakliotis</surname>
              <given-names>HZ</given-names>
            </name>
            <name>
              <surname>Monn</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Masterson</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Cary</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Pedrosa</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes</article-title>
          <source>Urology.</source>
          <year>2014</year>
          <volume>83</volume>
          <fpage>1112</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/j.urology.2013.12.035</pub-id>
          <pub-id pub-id-type="pmid">24582117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brower</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Anti-PD-L1 antibody active in metastatic bladder cancer</article-title>
          <source>Lancet Oncol.</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>e11</fpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(14)71167-2</pub-id>
          <pub-id pub-id-type="pmid">25638546</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boorjian</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Sheinin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Crispen</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Farmer</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Lohse</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Kuntz</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival</article-title>
          <source>Clin Cancer Res.</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>4800</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0731</pub-id>
          <pub-id pub-id-type="pmid">18676751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohno</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Akai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takaha</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kawahara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Plasmacytoid urothelial carcinoma of the bladder</article-title>
          <source>Int J Urol</source>
          <year>2006</year>
          <volume>13</volume>
          <issue>4</issue>
          <fpage>485</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2042.2006.01338.x</pub-id>
          <pub-id pub-id-type="pmid">16734884</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawashima</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ujike</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Miyoshi S: [Plasmacytoid urothelial carcinoma of the bladder: a case report]</article-title>
          <source>Nihon Hinyokika Gakkai Zasshi</source>
          <year>2009</year>
          <volume>100</volume>
          <issue>5</issue>
          <fpage>590</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">19663248</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fritsche</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Burger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Denzinger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Legal</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Goebell</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases</article-title>
          <source>J Urol</source>
          <year>2008</year>
          <volume>180</volume>
          <issue>5</issue>
          <fpage>1923</fpage>
          <lpage>1927</lpage>
          <pub-id pub-id-type="doi">10.1016/j.juro.2008.07.035</pub-id>
          <pub-id pub-id-type="pmid">18801525</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soylu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kutlu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gunes</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Urothelial carcinoma featuring lipid cell and plasmacytoid morphology with poor prognostic outcome</article-title>
          <source>Urology</source>
          <year>2005</year>
          <volume>65</volume>
          <issue>4</issue>
          <fpage>797</fpage>
          <pub-id pub-id-type="doi">10.1016/j.urology.2004.10.005</pub-id>
          <pub-id pub-id-type="pmid">15833536</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aldousari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sircar</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kassouf</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Plasmacytoid urothelial carcinoma of the bladder: a case report</article-title>
          <source>Cases J</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>6647</fpage>
          <pub-id pub-id-type="doi">10.1186/1757-1626-2-6647</pub-id>
          <pub-id pub-id-type="pmid">20181175</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tanigawa</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nakazawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hosomi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimazu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fushimi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Two cases of plasmacytoid variant of urothelial carcinoma of urinary bladder: systemic chemotherapy might be of benefit</article-title>
          <source>Int J Clin Oncol</source>
          <year>2011</year>
          <volume>16</volume>
          <issue>6</issue>
          <fpage>759</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="doi">10.1007/s10147-011-0240-4</pub-id>
          <pub-id pub-id-type="pmid">21732230</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
